Concepedia

Romain Ollier

RO

6

Publications

150

Citations

6

H-Index

2013

Active since

Affiliations

Glenmark Pharmaceuticals (Switzerland)(Current)

Glenmark Pharmaceuticals (India)

AC Immune (Switzerland)

Romain Ollier is an author at Glenmark Pharmaceuticals (Switzerland) specializing in neuroinflammation, neurodegenerative diseases, and neuroprotection.

ORCID

Top concepts

Publications per year

2013–2023

6

Publications

6

Immunoglobulin domain interface exchange as a platform technology for the generation of Fc heterodimers and bispecific antibodies

Darko Skegro, Cian Stutz, Romain Ollier et al. · Journal of Biological Chemistry · 2017 · 46 citations · Full text

Immunotherapy targeting the C-terminal domain of TDP-43 decreases neuropathology and confers neuroprotection in mouse models of ALS/FTD

Tariq Afroz, Elodie Chevalier, Mickaël Audrain et al. · Neurobiology of Disease · 2023 · 31 citations · Full text

, , +18

BEAT® the bispecific challenge: a novel and efficient platform for the expression of bispecific IgGs

Pierre Moretti, Darko Skegro, Romain Ollier et al. · BMC Proceedings · 2013 · 27 citations · Full text

Single-step Protein A and Protein G avidity purification methods to support bispecific antibody discovery and development

Romain Ollier, Paul Wassmann, Thierry Monney et al. · mAbs · 2019 · 22 citations · Full text

Targeting amyotrophic lateral sclerosis by neutralizing seeding-competent TDP-43 in CSF

Mickaël Audrain, Anne-Laure Egesipe, Noémie Tentillier et al. · Brain Communications · 2023 · 13 citations · Full text

Rows per page

1–5 of 6